[1]李木兰,石丹丹,张毅,等.茵陈蒿汤不同煎煮法对大鼠非酒精性脂肪性肝病疗效的影响研究[J].陕西中医,2025,46(6):741-745.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.004]
　LI Mulan,SHI Dandan,ZHANG Yi,et al.Therapeutic effect of different decocting methods of Yinchenhao decoction on non-alcoholic fatty liver disease rats[J].,2025,46(6):741-745.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.004]
点击复制

茵陈蒿汤不同煎煮法对大鼠非酒精性脂肪性肝病疗效的影响研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年6期
页码:
741-745
栏目:
基础研究
出版日期:
2025-06-05

文章信息/Info

Title:
Therapeutic effect of different decocting methods of Yinchenhao decoction on non-alcoholic fatty liver disease rats
作者:
李木兰; 石丹丹; 张毅; 刘杰; 马祺鑫; 艾碧琛; 龙飘
（湖南中医药大学，湖南 长沙 410218）
Author(s):
LI Mulan; SHI Dandan; ZHANG Yi; LIU Jie; MA Qixin; AI Bichen; LONG Piao
（Hunan University of Chinese Medicine，Changsha 410218,China）
关键词:
非酒精性脂肪性肝病; 茵陈蒿汤; 煎煮法; 先煎; 合煎; 后下
Keywords:
Nonalcoholic fatty liver disease; Yinchenhao decoction; Different decocting method; Decocting first; Decoting combined; Decoting later
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7369.2025.06.004
文献标志码:
A
摘要:
目的：探讨茵陈蒿汤不同煎煮法对非酒精性脂肪性肝病（NAFLD)大鼠治疗效果的差异。方法：使用高脂饮食法饲养SD大鼠12周制备非酒精性脂肪性肝病模型，随机分成空白组和实验组。将成功造模的实验组大鼠随机分为五组：模型组、西药组和茵陈蒿汤先煎组（简称先煎组）、茵陈蒿汤合煎组（简称合煎组）、茵陈蒿汤后下组（简称后下组）,每组6只。西药组和先煎组、合煎组、后下组大鼠予以相应药物灌胃干预4周,空白组、模型组等体积蒸馏水灌胃4周。灌胃结束后,生化检测大鼠血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、谷丙转氨酶（ALT）、谷草转氨酶（AST）、游离脂肪酸（FFA）水平，酶联免疫吸附测定法（ELISA）测定透明质酸酶（HAase）、Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（ColⅣ）、层粘连蛋白（LN）水平，苏木素-伊红（HE）染色观察肝脏组织病理改变。结果：与空白组比较,模型组大鼠的TC、LDL-C、ALT、AST、FFA、肝纤四项的表达均升高(P<0.01)，HDL-C降低；与模型组比较,西药组除TC、HDL-C外，其余各指标均降低，茵陈蒿汤三组大鼠血清TC、LDL-C、ALT、AST、FFA均降低（P<0.01），且先煎组、后下组的肝纤四项均降低（P<0.01）。先煎组、合煎组、后下组三组的LDL-C、HDL-C、ALT、AST存在差异，与先煎组比较，合煎组、后下组LDL-C水平较高及HDL-C水平较低，且后下组ALT、AST水平较高（P<0.01）；与合煎组比较，后下组ALT、AST水平较高，PCⅢ、ColⅣ、LN水平较低（P<0.01）。结论：不同煎煮法制备的茵陈蒿汤对NAFLD大鼠均具有保护作用，且存在一定疗效差异。可能由于药物共同煎煮时间不同，各有效成分溶出率不同，先煎组中降脂、保肝效果较合煎组、后下组更显著，合煎组保肝效果较后下组更显著，后下组较合煎组降低肝纤维化效果更显著，其保护肝脏的疗效差异机制可能与改善脂质代谢、改善肝脏纤维化有关。
Abstract:
Objective:To explore the differences in therapeutic effects of different decocting methods of Yinchenhao decoction on non-alcoholic fatty liver disease (NAFLD) rats.Methods:SD rats were randomly divided into blank group and experimental group.The experimental group were fed high-fat diet for 12 weeks to prepare non-alcoholic fatty liver disease model.Successful model rats were randomly divided into 5 groups:model group,western medicine group,Yinchenhao decoction decocting first group (abbreviation:decocting first group),Yinchenhao decoction decocting combined group (abbreviation:decocting combined group) and Yinchenhao decoction decocting later group (abbreviation:decocting later group)with 6 rats in each group.Blank group and model group were given equal volume of distilled water intragastric administration for 4 weeks,and the remaining 4 groups of rats were given corresponding drug gavage intervention for 4 weeks.After gavage,serum total cholesterol (TC),triglyceride (TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),alanine aminotransferase (ALT),glutamic aminotransferase (AST) and free fatty acid (FFA) levels were detected.The levels of hyaluronidase (HAase),type Ⅲ procollagen (PCⅢ),type Ⅳ collagen (ColⅣ) and laminin (LN) were determined by enzyme-linked immunosorbent assay (ELISA).The pathological changes of liver tissue were observed by hematoxylin-eosin (HE) staining.Results:Compared with blank group,the expressions of TC,LDL-C,ALT,AST,FFA and hepatic fiber in model group were all increased (P<0.01),while HDL-C was decreased.Compared with model group,western medicine group except TC,HDL-C,the other indexes were decreased,and the expression TC,LDL-C,ALT,AST and FFA of the Yinchenhao decoction three groups were decreased (P<0.01),and the liver fiber of the decocting first group and the decocting later group were decreased (P<0.01).There were differences in LDL-C,HDL-C,ALT and AST among the three groups.Compared with the decocting later group,LDL-C and HDL-C expressions were higher in the combined decoction group and the decocting later group,and ALT and AST expressions were higher in the decocting combined group (P<0.01).Compared with the decocting combined group,the expressions of ALT and AST in the decocting later group were higher,and the expressions of PCⅢ,ColⅣ and LN were lower (P<0.01).Conclusion:Yinchenhao decoction prepared by different decocting methods has protective effect on NAFLD rats,and there are some differences in the apeutic efficacy.Possibly due to the different time of co-decocting and the different dissolution rate of each active ingredient,the effect of lipid lowering and liver protection in the decocting first group was more significant than that in the decocting combined group and the decocting later group.The liver protection effect in the decocting combined group was more significant than that in the decocting later group.The decocting later group had a more significant effect on reducing liver fibrosis than that in the decocting combined group.The mechanism of the difference of its protective effect on liver may be related to the improvement of lipid metabolism and liver fibrosis.

参考文献/References:

[1]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
[2]TENG M L,NG C H,HUANG D Q,et al.Global incidence and prevalence of nonalcoholic fatty liver disease[J].Clin Mol Hepatol,2023,29:32-42.
[3]范建高,徐小元,南月敏,等.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].实用肝脏病杂志,2024,27(4):494-510.
[4]赵文霞,许二平,王宪波,等.非酒精性脂肪性肝炎中医诊疗指南[J].临床肝胆病杂志,2023,39(5):1041-1048.
[5]谭艳,周聪,黄柔,等.茵陈蒿汤对MKR鼠2型糖尿病合并非酒精性脂肪性肝病的作用[J].中国实验方剂学杂志,2021,27(21):105-113.
[6]谭婷,何栋,朱红梅,等.茵陈蒿汤对非酒精性脂肪性肝病大鼠细胞色素氧化酶P450-2E1影响研究[J].吉林中医药,2020,40(11):1505-1508.
[7]张仲景.金匮要略[M].北京：人民卫生出版社,2005：59.
[8]北京中医医院.关幼波临床经验选[M].北京：人民卫生出版社，2006：9.
[9]汪丹丹,陈文静,贾步云,等.非酒精性脂肪性肝病动物模型研究进展[J].中国实验方剂学杂志,2021,27(23):245-250.
[10]陈芮莹,林以宁.肝脏脂质代谢在非酒精性脂肪性肝病发生发展中的生物学机制[J].江西医药,2021,56(3):399-401.
[11]郭亮,汤其群.非酒精性脂肪肝发病机制和治疗的研究进展[J].生命科学,2018,30(11):1165-1172.
[12]赵梦溪,罗斌,吕建瑞,等.隐丹参酮治疗小鼠非酒精性脂肪性肝病效果及机制研究[J].陕西医学杂志,2023,52(9):1135-1139，1144.
[13]延华,柴春艳,张丹,等.基于JNK信号通路探讨自噬、胰岛素抵抗在非酒精性脂肪性肝病中的发病机制[J].陕西医学杂志,2023,52(11):1506-1510.
[14]徐灵胎.医学源流论[M].北京：中国中医药出版社,2008：43.
[15]吴艳秋,刘宇灵,王秀清,等.经典名方易黄汤古代煎煮方法与现代煎煮方法的差异性分析[J].中国实验方剂学杂志,2023,29(3):152-159.
[16]王欢欢,唐璇,许静,等.半夏厚朴汤古法煎煮与现代煎煮的差异研究[J].时珍国医国药,2020,31(10):2386-2389.
[17]宋春景.补中益气汤不同煎煮方法对汤剂药效的影响[J].临床合理用药杂志,2022,15(4):70-72.
[18]汤婷,张喆,郑宇明,等.经方茵陈蒿汤的临床应用总结[J].中西医结合研究,2019,11(2):104-106.
[19]孙帅玲,马晓北.基于网络药理学探讨茵陈蒿汤治疗高脂血症作用机制[J].陕西中医,2021,42(12):1793-1797.
[20]王淑平,李艳芳,孙雪,等.茵陈蒿汤联合熊去氧胆酸治疗妊娠期肝内胆汁淤积症疗效及Th17/Treg失衡对妊娠结局的影响[J].陕西中医,2023,44(8):1074-1077.
[21]闫雅婕,王亚亚,梁轩,等.茵陈化学成分、药理作用及在肝胆疾病中的临床应用研究进展[J].中华中医药学刊,2024,42(11):237-248.
[22]陈榕,何梓炫,颜烨,等.栀子及其主要成分的药理及毒性作用研究进展[J].中草药,2023,54(18):6092-6105.
[23]张桥,陈艳琰,乐世俊,等.大黄炮制的历史沿革及对化学成分、传统药理作用影响的研究进展[J].中国中药杂志,2021,46(3):539-551.
[24]刘桂元,罗利亚,李晓,等.大黄蒽醌类化合物抗炎作用研究进展[J].中成药,2023,45(11):3693-3701.
[25]袁颢宸,劳秋荣,王宁.茵陈蒿汤的药理作用及临床应用[J].河南中医,2023,43(7):984-991.

相似文献/References:

[1]李京涛,焦俊喆,魏海梁,等.茵陈蒿汤对急性肝内胆汁淤积大鼠肠道黏膜屏障和NF-κB的影响*[J].陕西中医,2019,(5):547.
[2]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
　HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(6):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[3]唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,(10):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
　TANG Yinghui,YE Miaoqing,HE Jinyu,et al.Huazhi Fugan granule alleviates Kupffer cell inflammation by inhibiting TLR4/NF-κB/NLRP3 and improves nonalcoholic fatty liver disease[J].,2022,(6):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
[4]林先佳,王小锋,张媛媛,等.基于网络药理学和分子对接探讨肝脂平治疗非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(4):524.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.027]
[5]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮调节AMPK/Nrf2信号通路治疗小鼠非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(8):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
　ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Mechanism of cryptotanshinone regulates AMPK/Nrf2 signaling pathway to treat nonalcoholic fatty liver disease in mouse[J].,2023,(6):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
[6]杨 帆,李 娟,何 昉,等.利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响[J].陕西中医,2023,(10):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
　YANG Fan,LI Juan,HE Fang,et al.Lidan Tuihuang decoction on liver function,glycolipid metabolism,and serum adipose factors in the treatment of non alcoholic fatty liver disease[J].,2023,(6):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
[7]李秀秀,张玉佩,许春玲,等.基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点[J].陕西中医,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
　LI Xiuxiu,ZHANG Yupei,XU Chunling,et al.Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism[J].,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
[8]罗 艺,周晓玲,刘 琳,等.非酒精性脂肪性肝病中医治疗研究进展[J].陕西中医,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
　LUO Yi,ZHOU Xiaoling,LIU Lin,et al.Research progress on traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J].,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
[9]李倩,王石中,刘昊奇,等.名中医孙克伟从“阳化气不足，阴成形过度”辨治非酒精性脂肪性肝病[J].陕西中医,2025,46(6):826.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.022]
　LI Qian,WANG Shizhong,LIU Haoqi,et al.Distinguished TCM expert SUN Kewei’s treatment of nonalcoholic fatty liver disease based on theory of “insufficient yang qi transformation and excessive yin manifestation”[J].,2025,46(6):826.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.022]
[10]杜玉双,罗磊,韩博闻,等.基于“肠道-微生物群-肝脏”轴探讨中药调节肠道菌群治疗非酒精性脂肪性肝病研究进展[J].陕西中医,2025,46(6):857.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.029]
　DU Yushuang,LUO Lei,HAN Bowen,et al.Research progress on the regulation of gut microbiota by traditional Chinese medicine to treat non-alcoholic fatty liver disease based on the “gut-microbiota-liver” axis[J].,2025,46(6):857.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.029]

备注/Memo

备注/Memo:
湖南省卫生健康高层次人才重大科研专项（R2023130）；湖南省教育厅科研基金资助重点项目（18A215）；湖南省中医药管理局科研计划项目（D2022016）；湖南中医药大学中医学一流学科开放基金资助项目（2022ZYX09）
更新日期/Last Update: 2025-06-09